Jennifer A. Woyach, MD, discusses how pirtobrutinib compares against other Bruton tyrosine kinase inhibitors and delves into the next steps for the agent in the CLL/SLL space.
Jennifer A. Woyach, MD, a hematologist-oncologist, professor in the Division of Hematology at The Ohio State University, and co-leader of the Leukemia Research Program at The Ohio State University Comprehensive Cancer Center, discusses how pirtobrutinib (Jaypirca) compares against other Bruton tyrosine kinase (BTK) inhibitors and delves into the next steps for pirtobrutinib in the chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma space.
According to Woyach, pirtobrutinib stands out from other BTK inhibitors due to its unique mechanism of action. Its non-covalent mechanism can potentially lead to a better safety profile in this patient population.
The agent recently received accelerated approval for the treatment of CLL. While initial approval was granted for patients who progressed after treatment with both a BTK inhibitor and a BCL-2 inhibitor, further studies are underway to determine the drug's efficacy and safety in a wider range of patients with CLL.
Transcription:
0:10 | Pirtobrutinib should be thought of as distinct from the other commercially available BTK inhibitors because this is a non-covalent inhibitor, as opposed to the other ones, which are covalent inhibitors. An [adverse] effect profile might be a little bit better with pirtobrutinib because it is such a selective molecule. So far, it has only been tested in the post-covalent BTK inhibitor setting in large numbers of patients. This is the subset of patients where accelerated approval was achieved recently, so that is for patients with relapsed/refractory CLL, who have received both a prior BTK and a prior BCL-2 inhibitor.
0:45 | Pirtobrutinib just got accelerated approval in CLL. There are a number of phase 3 trials that are ongoing, either accruing patients or where we are just awaiting results. This is looking at pirtobrutinib in a number of different clinical settings from the relapsed/refractory setting all the way up through frontline disease.
Leslie Reviews Relevant Data for Treatment of Relapsed/Refractory CLL
May 8th 2024During a Case-Based Roundtable® event, Lori A. Leslie, MD, discussed Bruton tyrosine kinase inhibition options for a patient with relapsed/refractory chronic lymphocytic leukemia in the first article of a 2-part series.
Read More
Marks Explores Cardiac Toxicities and Dosing Concerns of BTK Inhibitors in CLL
April 26th 2024During a Case-Based Roundtable® event, Stanley M. Marks, MD, moderated a discussion on the impact of cardiac adverse events on patients who receive a Bruton tyrosine kinase inhibitor for chronic lymphocytic leukemia.
Read More
Considering the Durability of Zanubrutinib in Relapsed/Refractory CLL
April 11th 2024During a Case-Based Roundtable® event, Marc S. Hoffmann, MD, discussed his viewpoints on the use of Bruton tyrosine kinase inhibitors for patients with relapsed/refractory chronic lymphocytic leukemia and the efficacy behind zanubrutinib in the second article of a 2-part series.
Read More
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More